上海莼试生物技术有限公司
上海莼试生物技术有限公司
化学性质：
| 规格 | 10mM (in 1mL DMSO) 10mg 50mg 100mg |
| CAS | 119 |
| 别名 | GSK-2118436 Mesylate;GSK2118436 Mesylate;GSK 2118436 Mesylate;GSK 2118436B,Tafinlar, |
| 化学名 | N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid |
| 分子式 | C24H24F3N5O5S3 |
| 分子量 | 615.67 |
| 溶解度 | ≥ 30.75 mg/mL in DMSO, ≥ 2.74 mg/mL in EtOH with ultrasonic and warming |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice |
产品描述：
GSK2118436 is a selective BRAF V600E inhibitor. BRAF encodes a proto-oncogene B-Raf also known as serine/threonine protein kinase B-Raf. It is critical in regulating the MAPK/ERK signaling pathway. BRAF mutations frequently occur in many human cancers. [1, 2] BRAF V600E mutant is constitutively active, allowing MAPK/ERK activation independent of upstream cues. [3]
GSK2118436 binds to Raf family kinases and inhibits their activity. It is highly selective against B-Raf V600E with IC50 of 0.8 nM, compared to wild type B-Raf and c-Raf with IC50s of 3.2 nM and 5.0 nM, respectively. [4]
GSK2118436 treatment shows selective inhibition of MAPK/ERK activation, proliferation, transformation and tumorigenicity. FDA approved GSK2118436 as a single agent treatment for advanced melanoma with BRAF V600E mutation on May 30, 2013.
GSK2118436 can be taken orally.
特别提醒：
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。
联系人：高小姐
手 机：13585831301
Q Q：3004967995
座 机：021-59541103
传 真：021-60443211
地 址：上海嘉定区嘉罗公路1661
